3 active not recruiting, 3 recruiting. 6 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 3, Recruiting 3 |
| Phase 1 | 5 | Active not recruiting 3, Recruiting 2 |
Follow AZD5305: new trials by email Literature Review of AZD5305 trials Research Report on AZD5305
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs AZD9750, AZD5305 - Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 6 | 2026-01-27 | 2026-10-02 |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Recruiting | SWOG Cancer Research Network | 900 | 2025-11-06 | 2026-03-30 |
| Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors Torvutatug samrotecan, Saruparib, Bevacizumab - Ovarian Cancer, Lung Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 622 | 2023-06-05 | 2026-10-05 |
| Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer AZD5305, Enzalutamide, Abiraterone Acetate - Metastatic Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 174 | 2022-06-02 | 2026-08-26 |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib) - Breast Cancer, Biliary Tract Carcinoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 460 | 2021-10-18 | 2026-10-13 |
| Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies AZD5305, Paclitaxel, Carboplatin - Ovarian Cancer, Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 702 | 2020-11-12 | 2026-09-21 |
Endometrial Neoplasms (3) · Ovarian Neoplasms (3) · Prostatic Neoplasms (3) · Breast Neoplasms (2) · Adenocarcinoma of Lung (1) · Biliary Tract Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1) · Uterine Cervical Neoplasms (1)
AstraZeneca (5) · SWOG Cancer Research Network (1)
United States (6) · Australia (5) · United Kingdom (5) · Japan (4) · Canada (3) · China (3) · Italy (3) · South Korea (3) · Spain (3) · Hungary (2) · Poland (2) · Taiwan (2) · Belgium (1) · Czechia (1) · Germany (1)
Anne C Chiang (1) · Funda Meric-Bernstam, MD (1) · Timothy Yap (1)
2023 (1), U10CA180888 (1)